Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.
1. A method of treating a subject suffering from cardiac arrhythmia, comprising:
(a) monitoring an incidence of said cardiac arrhythmia in said subject with aid of an electronic monitoring device;
(b) administering an aerosolized pharmaceutical composition from an aerosolization device to said subject, wherein said aerosolized pharmaceutical composition comprises a therapeutically effective amount of at least one antiarrhythmic or a pharmaceutically acceptable salt thereof; and
(c) receiving a treatment recommendation from said electronic monitoring device after said electronic monitoring device verifies said administering of said aerosolized pharmaceutical composition.
2. The method of claim 1 , wherein said aerosolization device comprises an inhaler.
3. The method of claim 2 , wherein said inhaler is in communication with said electronic monitoring device.
4. The method of claim 2 , wherein said inhaler comprises a digital display.
5. The method of claim 2 , wherein said inhaler comprises auditory means capable of communicating to said subject.
6. The method of claim 1 , wherein said administering is performed by said subject.
7. The method of claim 1 , wherein said administering is performed by a healthcare professional.
8. The method of claim 1 , wherein said at least one antiarrhythmic or pharmaceutically acceptable salt thereof is a class I antiarrhythmic, class II antiarrhythmic, class III antiarrhythmic, class IV antiarrhythmic, class V antiarrhythmic, or a salt of any of these.
9. The method of claim 1 , wherein said at least one antiarrhythmic or pharmaceutically acceptable salt thereof comprises flecainide acetate.
10. The method of claim 1 , wherein said electronic monitoring device waits for a confirmation from a healthcare provider prior to allowing said administering of said aerosolized pharmaceutical composition to said subject.
11. The method of claim 1 , wherein said therapeutically effective amount is an amount sufficient to convert said arrhythmia to normal sinus rhythm.
12. The method of claim 1 , wherein said therapeutically effective amount is at least about 30 mg of said at least one antiarrhythmic or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein said therapeutically effective amount converts said arrhythmia to normal sinus rhythm from about 0 secs to about 2 hours after said administration.
14. The method of claim 1 , wherein said electronic monitoring device is in communication with an electronic monitoring chip that is inserted into said subject or worn by said subject.
15. The method of claim 1 , wherein said electronic monitoring device comprises a digital display or auditory means capable of communicating to said subject.
16. The method of claim 1 , wherein said electronic monitoring device is a smartphone.
17. The method of claim 1 , wherein said treatment recommendation comprises stopping said administering when said cardiac arrhythmia is converted to a normal sinus rhythm.
18. The method of claim 1 , wherein said treatment recommendation comprises seeking medical attention when said cardiac arrhythmia does not respond to said administering.